SEC Form 4

FORM 4		UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940	OMB APPROVAL OMB Number: 3235-0287 Estimated average burden hours per response: 0.5
	Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

1. Name and Address of Reporting Person* SCHUHSLER HELMUT (Last) (First) (Middle) C/O TVM CAPITAL MAXIMILIANSTRASSE 35C (Street) MUNICH 2M 80539 (City) (State) (Zip)	2. Issuer Name and Ticker or Trading Symbol ENANTA PHARMACEUTICALS INC [ ENTA ]	5. Relationship of Reporting Person(s) to Issuer (Check all applicable) X Director X 10% Owner Officer (give title below) Other (specify below)
	3. Date of Earliest Transaction (Month/Day/Year) 03/26/2013
	4. If Amendment, Date of Original Filed (Month/Day/Year)	6. Individual or Joint/Group Filing (Check Applicable Line) X Form filed by One Reporting Person Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	03/26/2013		C		236,065	A	(1)	236,065	I	See Note 5.(5)(8)
Common Stock	03/26/2013		C		351,014	A	(2)	587,079	I	See Note 6.(6)(9)
Common Stock	03/26/2013		C		155,316	A	(2)	742,395	I	See Note 5.(5)(10)
Common Stock	03/26/2013		C		172,030	A	(3)	914,425	I	See Note 6.(6)(11)
Common Stock	03/26/2013		C		1,006,498	A	(3)	1,920,923	I	See Note 7.(7)(12)
Common Stock	03/26/2013		C		478,247	A	(4)	2,399,170	I	See Note 7.(7)(13)
Common Stock	03/26/2013		P		132,949	A	$14	2,532,119	I	See Note 7.(7)(14)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Series C Convertible Preferred Stock	(1)	03/26/2013		C			1,017,442	(1)	(1)	Common Stock	236,065	$0	0	I	See Note 5.(5)
Series D Convertible Preferred Stock	(2)	03/26/2013		C			1,130,000	(2)	(2)	Common Stock	351,014	$0	500,000	I	See Note 6.(6)
Series D Convertible Preferred Stock	(2)	03/26/2013		C			500,000	(2)	(2)	Common Stock	155,316	$0	0	I	See Note 5.(5)
Series E Convertible Preferred Stock	(3)	03/26/2013		C			563,503	(3)	(3)	Common Stock	172,030	$0	3,296,888	I	See Note 6.(6)
Series E Convertible Preferred Stock	(3)	03/26/2013		C			3,296,888	(3)	(3)	Common Stock	1,006,498	$0	0	I	See Note 7.(7)
Series G-2 Convertible Preferred Stock	(4)	03/26/2013		C			2,061,246	(4)	(4)	Common Stock	478,247	$0	0	I	See Note 7.(7)

Explanation of Responses:

1. The Series C Convertible Preferred Stock automatically converted into Enanta Pharmaceuticals, Inc. ("Enanta") Common Stock on a 0.23202-for-one basis automatically upon the closing of the initial public offering of Enanta without payment of further consideration and had no expiration date.

2. The Series D Convertible Preferred Stock automatically converted into Enanta Common Stock on a 0.31063-for-one basis automatically upon the closing of the initial public offering of Enanta without payment of further consideration and had no expiration date.

3. The Series E Convertible Preferred Stock automatically converted into Enanta Common Stock on a 0.30529-for-one basis automatically upon the closing of the initial public offering of Enanta without payment of further consideration and had no expiration date.

4. The Series G-2 Convertible Preferred Stock automatically converted into Enanta Common Stock on a 0.23202-for-one basis automatically upon the closing of the initial public offering of Enanta without payment of further consideration and had no expiration date.

5. The shares are directly held by TVM Medical Ventures GmbH & Co. KG ("Medical Ventures"), the general partner of which is TVM Capital GmbH ("TVM Capital"), for which Helmut Schuhsler ("Schuhsler"), one member of the investment committee of TVM Capital, shares voting and investment authority over the shares held by Medical Ventures with the other member of the investment committee. Schuhsler disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein, if any.

6. The shares are directly held by TVM IV GmbH & Co. KG ("TVM IV"), the managing limited partner of which is TVM IV Management GmbH & Co. KG ("TVM IV Management"), for which Schuhsler, one member of the investment committee of TVM IV Management, shares voting and investment authority over the shares held by TVM IV with the other members of the investment committee. Schuhsler disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein, if any.

7. The shares are directly held by TVM V Life Science Ventures GmbH & Co. KG ("TVM V"), the managing limited partner of which is TVM V Life Science Ventures Management GmbH & Co. KG ("TVM V Management"), for which for which Schuhsler, one member of the investment committee of TVM V Management, shares voting and investment authority over the shares held by TVM V with the other members of the investment committee. Schuhsler disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein, if any.

8. Includes 236,065 shares held directly by Medical Ventures.

9. Includes 236,065 shares held directly by Medical Ventures and 351,014 shares held directly by TVM IV.

10. Includes 391,381 shares held directly by Medical Ventures and 351,014 shares held directly by TVM IV.

11. Includes 391,381 shares held directly by Medical Ventures and 523,044 shares held directly by TVM IV.

12. Includes 391,381 shares held directly by Medical Ventures, 523,044 shares held directly by TVM IV and 1,006,498 shares held directly by TVM V.

13. Includes 391,381 shares held directly by Medical Ventures, 523,044 shares held directly by TVM IV and 1,484,745 shares held directly by TVM V.

14. Includes 391,381 shares held directly by Medical Ventures, 523,044 shares held directly by TVM IV and 1,617,694 shares held directly by TVM V.

Remarks:

	Rolf Starck by power of attorney for Helmut Schuhsler	03/28/2013
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

POWER OF ATTORNEY





KNOWN ALL MEN BY THESE PRESENTS, that the undersigned hereby makes, constitutes and appoints

Rolf Starck, as the undersigned's true and lawful attorney-in-fact and agent for him and in his

name, place and stead, in any and all capacities, to sign any and all documents relating to any

and all Securities and Exchange Commission filings which may be required, granting unto such

attorney-in-fact and agent full power and authority to do and perform each and every act and

thing requisite and necessary to be done in and about the premises, as fully to all intents and

purposes as he might or could do in person, thereby ratifying and confirming all that such

attorney-in-fact may lawfully do or cause to be done by virtue hereof.



This power shall continue in effect until terminated in writing.





By: /s/ Helmut Schuhsler

 Helmut Schuhsler





Dated: March 19, 2013